We are proud to announce that PhenoPath is now a Quest Diagnostics Company.
IHC
Methodology: IHC
Clinical Significance:
Identifies: p63, a gene in the p53 family, that is expressed in myoepithelial cells, squamous and transitional epithelial cells, and the basal layer of prostate and other epithelial tissues. Identification of p63, or its absence, can be useful in identifying the presence of invasive carcinoma in breast and prostate, as well as the identification of squamous and transitional cell carcinomas.
Subcellular Localization: Nuclear
Organ: Breast, Genitourinary, Lung, Prostate, Skin & Mucosa
Disease State: Breast Cancer, Carcinomas of Unknown Primary, Mesothelioma vs. Adenocarcinoma, Non Small Cell Lung Carcinoma (NSCLC), Spindle Cell Tumors / Sarcoma Subtyping
CPT Code(s): 88342 or 88341 (reference only; CPTs may vary)
Turnaround Time: Within 1-2 business days of receipt
Schedule: Monday - Friday
Specimen Requirements:
• Formalin-fixed, paraffin-embedded (FFPE) tissue block or cell block - OR -
• 1 unstained slide for each test requested plus 3-4 additional unstained slides cut at 4µm